閉経後膣萎縮治療薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Postmenopausal Vaginal Atrophy Therapeutics Market Insights, Forecast to 2028

• レポートコード：QY2207E09276 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥725,200 (USD4,900)	▷ お問い合わせ
Multi User	￥1,087,800 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,450,400 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の閉経後膣萎縮治療薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に閉経後膣萎縮治療薬の世界市場のxxx％を占める「エストロゲン系治療薬」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の閉経後膣萎縮治療薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの閉経後膣萎縮治療薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの閉経後膣萎縮治療薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 閉経後膣萎縮治療薬のグローバル主要メーカーには、Endoceutics、Accord Healthcare、Pfizer、Novo Nordisk、Teva Pharmaceuticals、Shionogi、Bionovo、QuatRx Pharmaceutical Company、Bayer AG、TherapeuticsMDなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 閉経後膣萎縮治療薬市場は、種類と用途によって区分されます。世界の閉経後膣萎縮治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 エストロゲン系治療薬、非エストロゲン系治療薬 【用途別セグメント】 病院、専門クリニック 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 閉経後膣萎縮治療薬製品概要 - 種類別市場（エストロゲン系治療薬、非エストロゲン系治療薬） - 用途別市場（病院、専門クリニック） - 調査の目的 ・エグゼクティブサマリー - 世界の閉経後膣萎縮治療薬販売量予測2017-2028 - 世界の閉経後膣萎縮治療薬売上予測2017-2028 - 閉経後膣萎縮治療薬の地域別販売量 - 閉経後膣萎縮治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別閉経後膣萎縮治療薬販売量 - 主要メーカー別閉経後膣萎縮治療薬売上 - 主要メーカー別閉経後膣萎縮治療薬価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（エストロゲン系治療薬、非エストロゲン系治療薬） - 閉経後膣萎縮治療薬の種類別販売量 - 閉経後膣萎縮治療薬の種類別売上 - 閉経後膣萎縮治療薬の種類別価格 ・用途別市場規模（病院、専門クリニック） - 閉経後膣萎縮治療薬の用途別販売量 - 閉経後膣萎縮治療薬の用途別売上 - 閉経後膣萎縮治療薬の用途別価格 ・北米市場 - 北米の閉経後膣萎縮治療薬市場規模（種類別、用途別） - 主要国別の閉経後膣萎縮治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの閉経後膣萎縮治療薬市場規模（種類別、用途別） - 主要国別の閉経後膣萎縮治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の閉経後膣萎縮治療薬市場規模（種類別、用途別） - 主要国別の閉経後膣萎縮治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の閉経後膣萎縮治療薬市場規模（種類別、用途別） - 主要国別の閉経後膣萎縮治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの閉経後膣萎縮治療薬市場規模（種類別、用途別） - 主要国別の閉経後膣萎縮治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Endoceutics、Accord Healthcare、Pfizer、Novo Nordisk、Teva Pharmaceuticals、Shionogi、Bionovo、QuatRx Pharmaceutical Company、Bayer AG、TherapeuticsMD ・産業チェーン及び販売チャネル分析 - 閉経後膣萎縮治療薬の産業チェーン分析 - 閉経後膣萎縮治療薬の原材料 - 閉経後膣萎縮治療薬の生産プロセス - 閉経後膣萎縮治療薬の販売及びマーケティング - 閉経後膣萎縮治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 閉経後膣萎縮治療薬の産業動向 - 閉経後膣萎縮治療薬のマーケットドライバー - 閉経後膣萎縮治療薬の課題 - 閉経後膣萎縮治療薬の阻害要因 ・主な調査結果

Postmenopausal vaginal atrophy (PVA), also referred to as postmenopausal atrophic vaginitis, caused by the vaginal walls’ drying, thinning, and inflammation due to reduced estrogen levels. Women with this disorder are more vulnerable to problems of urinary system and chronic infection of vaginal linings. A variety of medications and therapies available in market that focuses on the underlying cause as well as the symptoms of the condition. These therapies also helps women to improve their quality of life.
Market Analysis and Insights: Global Postmenopausal Vaginal Atrophy Therapeutics Market
The global Postmenopausal Vaginal Atrophy Therapeutics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Estrogen-based Drugs accounting for % of the Postmenopausal Vaginal Atrophy Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Postmenopausal Vaginal Atrophy Therapeutics market size is valued at US$ million in 2021, while the North America and Europe Postmenopausal Vaginal Atrophy Therapeutics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Postmenopausal Vaginal Atrophy Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Postmenopausal Vaginal Atrophy Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Postmenopausal Vaginal Atrophy Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Postmenopausal Vaginal Atrophy Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Postmenopausal Vaginal Atrophy Therapeutics market.
Global Postmenopausal Vaginal Atrophy Therapeutics Scope and Market Size
Postmenopausal Vaginal Atrophy Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Postmenopausal Vaginal Atrophy Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Estrogen-based Drugs
Non-estrogen-based Drugs
Segment by Application
Hospital
Specialist Clinic
By Company
Endoceutics
Accord Healthcare
Pfizer
Novo Nordisk
Teva Pharmaceuticals
Shionogi
Bionovo
QuatRx Pharmaceutical Company
Bayer AG
TherapeuticsMD
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

---

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Estrogen-based Drugs
1.2.3 Non-estrogen-based Drugs
1.3 Market by Application
1.3.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Specialist Clinic
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Perspective (2017-2028)
2.2 Postmenopausal Vaginal Atrophy Therapeutics Growth Trends by Region
2.2.1 Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Postmenopausal Vaginal Atrophy Therapeutics Market Dynamics
2.3.1 Postmenopausal Vaginal Atrophy Therapeutics Industry Trends
2.3.2 Postmenopausal Vaginal Atrophy Therapeutics Market Drivers
2.3.3 Postmenopausal Vaginal Atrophy Therapeutics Market Challenges
2.3.4 Postmenopausal Vaginal Atrophy Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Revenue
3.1.1 Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Postmenopausal Vaginal Atrophy Therapeutics Revenue
3.4 Global Postmenopausal Vaginal Atrophy Therapeutics Market Concentration Ratio
3.4.1 Global Postmenopausal Vaginal Atrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Therapeutics Revenue in 2021
3.5 Postmenopausal Vaginal Atrophy Therapeutics Key Players Head office and Area Served
3.6 Key Players Postmenopausal Vaginal Atrophy Therapeutics Product Solution and Service
3.7 Date of Enter into Postmenopausal Vaginal Atrophy Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Postmenopausal Vaginal Atrophy Therapeutics Breakdown Data by Type
4.1 Global Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Type (2023-2028)
5 Postmenopausal Vaginal Atrophy Therapeutics Breakdown Data by Application
5.1 Global Postmenopausal Vaginal Atrophy Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size (2017-2028)
6.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type
6.2.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022)
6.2.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028)
6.2.3 North America Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type (2017-2028)
6.3 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application
6.3.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022)
6.3.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028)
6.3.3 North America Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application (2017-2028)
6.4 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country
6.4.1 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022)
6.4.2 North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size (2017-2028)
7.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type
7.2.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022)
7.2.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028)
7.2.3 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type (2017-2028)
7.3 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application
7.3.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022)
7.3.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028)
7.3.3 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application (2017-2028)
7.4 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country
7.4.1 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022)
7.4.2 Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type
8.2.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type (2017-2028)
8.3 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application
8.3.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application (2017-2028)
8.4 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region
8.4.1 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size (2017-2028)
9.2 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type
9.2.1 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022)
9.2.2 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028)
9.2.3 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type (2017-2028)
9.3 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application
9.3.1 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022)
9.3.2 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028)
9.3.3 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application (2017-2028)
9.4 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country
9.4.1 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022)
9.4.2 Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type
10.2.1 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type (2017-2028)
10.3 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application
10.3.1 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application (2017-2028)
10.4 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country
10.4.1 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Endoceutics
11.1.1 Endoceutics Company Details
11.1.2 Endoceutics Business Overview
11.1.3 Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.1.4 Endoceutics Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.1.5 Endoceutics Recent Developments
11.2 Accord Healthcare
11.2.1 Accord Healthcare Company Details
11.2.2 Accord Healthcare Business Overview
11.2.3 Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.2.4 Accord Healthcare Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.2.5 Accord Healthcare Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.3.4 Pfizer Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.3.5 Pfizer Recent Developments
11.4 Novo Nordisk
11.4.1 Novo Nordisk Company Details
11.4.2 Novo Nordisk Business Overview
11.4.3 Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.4.4 Novo Nordisk Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.4.5 Novo Nordisk Recent Developments
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Details
11.5.2 Teva Pharmaceuticals Business Overview
11.5.3 Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.5.4 Teva Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.5.5 Teva Pharmaceuticals Recent Developments
11.6 Shionogi
11.6.1 Shionogi Company Details
11.6.2 Shionogi Business Overview
11.6.3 Shionogi Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.6.4 Shionogi Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.6.5 Shionogi Recent Developments
11.7 Bionovo
11.7.1 Bionovo Company Details
11.7.2 Bionovo Business Overview
11.7.3 Bionovo Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.7.4 Bionovo Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.7.5 Bionovo Recent Developments
11.8 QuatRx Pharmaceutical Company
11.8.1 QuatRx Pharmaceutical Company Company Details
11.8.2 QuatRx Pharmaceutical Company Business Overview
11.8.3 QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.8.4 QuatRx Pharmaceutical Company Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.8.5 QuatRx Pharmaceutical Company Recent Developments
11.9 Bayer AG
11.9.1 Bayer AG Company Details
11.9.2 Bayer AG Business Overview
11.9.3 Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.9.4 Bayer AG Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.9.5 Bayer AG Recent Developments
11.10 TherapeuticsMD
11.10.1 TherapeuticsMD Company Details
11.10.2 TherapeuticsMD Business Overview
11.10.3 TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Introduction
11.10.4 TherapeuticsMD Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
11.10.5 TherapeuticsMD Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Estrogen-based Drugs
Table 3. Key Players of Non-estrogen-based Drugs
Table 4. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Region (2017-2022)
Table 8. Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Region (2023-2028)
Table 10. Postmenopausal Vaginal Atrophy Therapeutics Market Trends
Table 11. Postmenopausal Vaginal Atrophy Therapeutics Market Drivers
Table 12. Postmenopausal Vaginal Atrophy Therapeutics Market Challenges
Table 13. Postmenopausal Vaginal Atrophy Therapeutics Market Restraints
Table 14. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Share by Players (2017-2022)
Table 16. Global Top Postmenopausal Vaginal Atrophy Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Therapeutics as of 2021)
Table 17. Ranking of Global Top Postmenopausal Vaginal Atrophy Therapeutics Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Postmenopausal Vaginal Atrophy Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Postmenopausal Vaginal Atrophy Therapeutics Product Solution and Service
Table 21. Date of Enter into Postmenopausal Vaginal Atrophy Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share by Type (2017-2022)
Table 25. Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Market Share by Type (2023-2028)
Table 27. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Share by Application (2017-2022)
Table 29. Global Postmenopausal Vaginal Atrophy Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Postmenopausal Vaginal Atrophy Therapeutics Revenue Share by Application (2023-2028)
Table 31. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 32. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 33. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 34. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 35. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 38. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 39. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 40. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 41. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 42. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 49. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 50. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 51. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 52. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 53. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 54. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 56. Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 61. Endoceutics Company Details
Table 62. Endoceutics Business Overview
Table 63. Endoceutics Postmenopausal Vaginal Atrophy Therapeutics Product
Table 64. Endoceutics Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 65. Endoceutics Recent Developments
Table 66. Accord Healthcare Company Details
Table 67. Accord Healthcare Business Overview
Table 68. Accord Healthcare Postmenopausal Vaginal Atrophy Therapeutics Product
Table 69. Accord Healthcare Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 70. Accord Healthcare Recent Developments
Table 71. Pfizer Company Details
Table 72. Pfizer Business Overview
Table 73. Pfizer Postmenopausal Vaginal Atrophy Therapeutics Product
Table 74. Pfizer Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 75. Pfizer Recent Developments
Table 76. Novo Nordisk Company Details
Table 77. Novo Nordisk Business Overview
Table 78. Novo Nordisk Postmenopausal Vaginal Atrophy Therapeutics Product
Table 79. Novo Nordisk Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 80. Novo Nordisk Recent Developments
Table 81. Teva Pharmaceuticals Company Details
Table 82. Teva Pharmaceuticals Business Overview
Table 83. Teva Pharmaceuticals Postmenopausal Vaginal Atrophy Therapeutics Product
Table 84. Teva Pharmaceuticals Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 85. Teva Pharmaceuticals Recent Developments
Table 86. Shionogi Company Details
Table 87. Shionogi Business Overview
Table 88. Shionogi Postmenopausal Vaginal Atrophy Therapeutics Product
Table 89. Shionogi Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 90. Shionogi Recent Developments
Table 91. Bionovo Company Details
Table 92. Bionovo Business Overview
Table 93. Bionovo Postmenopausal Vaginal Atrophy Therapeutics Product
Table 94. Bionovo Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 95. Bionovo Recent Developments
Table 96. QuatRx Pharmaceutical Company Company Details
Table 97. QuatRx Pharmaceutical Company Business Overview
Table 98. QuatRx Pharmaceutical Company Postmenopausal Vaginal Atrophy Therapeutics Product
Table 99. QuatRx Pharmaceutical Company Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 100. QuatRx Pharmaceutical Company Recent Developments
Table 101. Bayer AG Company Details
Table 102. Bayer AG Business Overview
Table 103. Bayer AG Postmenopausal Vaginal Atrophy Therapeutics Product
Table 104. Bayer AG Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 105. Bayer AG Recent Developments
Table 106. TherapeuticsMD Company Details
Table 107. TherapeuticsMD Business Overview
Table 108. TherapeuticsMD Postmenopausal Vaginal Atrophy Therapeutics Product
Table 109. TherapeuticsMD Revenue in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 110. TherapeuticsMD Recent Developments
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Estrogen-based Drugs Features
Figure 3. Non-estrogen-based Drugs Features
Figure 4. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Application: 2021 VS 2028
Figure 5. Hospital Case Studies
Figure 6. Specialist Clinic Case Studies
Figure 7. Postmenopausal Vaginal Atrophy Therapeutics Report Years Considered
Figure 8. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 9. Global Postmenopausal Vaginal Atrophy Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 10. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Region: 2021 VS 2028
Figure 11. Global Postmenopausal Vaginal Atrophy Therapeutics Market Share by Players in 2021
Figure 12. Global Top Postmenopausal Vaginal Atrophy Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Postmenopausal Vaginal Atrophy Therapeutics as of 2021)
Figure 13. The Top 10 and 5 Players Market Share by Postmenopausal Vaginal Atrophy Therapeutics Revenue in 2021
Figure 14. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 15. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size Market Share by Type (2017-2028)
Figure 16. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size Market Share by Application (2017-2028)
Figure 17. North America Postmenopausal Vaginal Atrophy Therapeutics Market Size Share by Country (2017-2028)
Figure 18. United States Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 19. Canada Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 21. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size Market Share by Type (2017-2028)
Figure 22. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size Market Share by Application (2017-2028)
Figure 23. Europe Postmenopausal Vaginal Atrophy Therapeutics Market Size Share by Country (2017-2028)
Figure 24. Germany Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. France Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. U.K. Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Italy Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Russia Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Nordic Countries Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Asia-Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 31. Asia Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size Market Share by Type (2017-2028)
Figure 32. Asia Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size Market Share by Application (2017-2028)
Figure 33. Asia Pacific Postmenopausal Vaginal Atrophy Therapeutics Market Size Share by Region (2017-2028)
Figure 34. China Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Japan Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. South Korea Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Southeast Asia Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. India Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Australia Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 40. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 41. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size Market Share by Type (2017-2028)
Figure 42. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size Market Share by Application (2017-2028)
Figure 43. Latin America Postmenopausal Vaginal Atrophy Therapeutics Market Size Share by Country (2017-2028)
Figure 44. Mexico Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Brazil Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Middle East & Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 47. Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size Market Share by Type (2017-2028)
Figure 48. Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size Market Share by Application (2017-2028)
Figure 49. Middle East and Africa Postmenopausal Vaginal Atrophy Therapeutics Market Size Share by Country (2017-2028)
Figure 50. Turkey Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 51. Saudi Arabia Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. UAE Postmenopausal Vaginal Atrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Endoceutics Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
Figure 54. Accord Healthcare Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
Figure 55. Pfizer Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
Figure 56. Novo Nordisk Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
Figure 57. Teva Pharmaceuticals Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
Figure 58. Shionogi Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
Figure 59. Bionovo Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
Figure 60. QuatRx Pharmaceutical Company Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
Figure 61. Bayer AG Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
Figure 62. TherapeuticsMD Revenue Growth Rate in Postmenopausal Vaginal Atrophy Therapeutics Business (2017-2022)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

---